Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
I.M. Sechenov First Moscow State Medical University
With
Moscow Regional Research and Clinical Institute (MONIKI)
Pirogov Russian National Research Medical University
Age
50–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
prostate adenocarcinoma verified by at least 12 core biopsy
patient must understand the sense of research, agree to participate and sign a form of agreement
low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA\<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
not more than 33% cores with adenocarcinoma
You may not be if
previous treatment of prostate cancer
other prostatic malignant neoplasms
other oncological diseases
treatment with 5-alfa-reductase inhibitors
patient's refuse to continue study
patient's desire to begin treatment
Clareo Health | Active Surveillance for Low Risk Prostate Cancer
